Drug Profile
Research programme: Therapore-based vaccines - AVANT
Alternative Names: Therapore®-based vaccines research programme - AVANTLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator AVANT Immunotherapeutics
- Class Cancer vaccines; Viral hepatitis vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer; Hepatitis B; Hepatitis C
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-B in USA
- 04 Nov 2017 No recent reports of development identified for preclinical development in Hepatitis-B(Prevention) in USA